FBIO
Fortress Biotech, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Fortress Biotech, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIn March 2025, Avenue received a "notice of intent to terminate" letter from AnnJi, the licensor of AJ201, with respect to the license agreement under which Avenue was granted rights to the product candidate.
FBIO 10-Kaccession 0001104659-26-037874
SentenceBAER-101 was originally licensed by Baergic from AstraZeneca AB and will be referred to as AXS-17 by Axsome going forward.
FBIO 10-Kaccession 0001104659-26-037874
SentenceAmortization of acquired intangible assets increased by $0.8 million, or 24%, to $4.3 million for the year ended December 31, 2025, from $3.4 million for the year ended December 31, 2024, driven by the addition of the Emrosi acquired intangible asset upon Journey's payment to DRL of the milestone payment triggered by the FDA's approval of Emrosi in November 2024.
FBIO 10-Kaccession 0001104659-26-037874
SentenceOn February 18, 2026, our partner company Avenue entered into a license agreement with Duke University ("Duke"), whereby Avenue obtained an exclusive worldwide license (the "ATX-04 License") from Duke to certain patents and know-how pertaining to clenbuterol for the treatment of lysosomal storage diseases.
FBIO 10-Kaccession 0001104659-26-037874
SentenceThe trial is funded by a grant from the National Cancer Institute ("NCI") (NCT06059391).
FBIO 10-Kaccession 0001104659-26-037874
SentenceOur subsidiary, Cyprium, is eligible to receive commercial milestones and royalties on net sales of ZYCUBO from Sentynl, and was also transferred a Rare Pediatric Disease Priority Review Voucher ("PRV") from Sentynl subsequent to the approval, which was sold for $205 million in gross proceeds.
FBIO 10-Kaccession 0001104659-26-037874
SentenceIn November 2025, Avenue announced it had entered into an agreement for Baergic to be acquired by Axsome, including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator ("PAM").
SentenceOn October 5, 2021, AstraZeneca acquired Caelum Biosciences, Inc. ("Caelum"), a former subsidiary of Fortress for an upfront payment of approximately $135 million paid to Caelum shareholders, of which approximately $56.9 million was paid to Fortress.
SentenceUnder the Transaction Documents, Urica transferred substantially all intellectual property rights in dotinurad to Crystalys.
FBIO 10-Kaccession 0001104659-26-037874
SentenceJMC began supplying Amzeeq to Cutia in August 2025 under an agreement with Cutia.
FBIO 10-Kaccession 0001104659-26-037874
SentenceIn December 2023, Cyprium completed the asset transfer of CUTX-101 to Sentynl.
FBIO 10-Kaccession 0001104659-26-037874
SentenceIn May 2025, our former subsidiary, Checkpoint, was acquired by Sun Pharma for $4.10 per share in cash plus a contingent value right of up to $0.70 per share upon the achievement of EU approval of Checkpoint's principal drug product candidate.
FBIO 10-Kaccession 0001104659-26-037874
Fortress Biotech, Inc.
1.91
Fortress Biotech has 6 disclosed suppliers and 7 disclosed customers in SEC filings.
Linked news
Expected move
No implied move.